ACUMEN PHARMACEUTICALS

Acumen Pharmaceuticals Completes Enrollment in Phase 1 Trial of ACU193, First Monoclonal Antibody Developed to Selectively Target Toxic Aβ Oligomers in Patients with Early Alzheimer’s Disease

13 Feb 2023 07:00:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals Appoints Derrell Porter, M.D., to its Board of Directors

04 Jan 2023 07:00:02 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals Reports Third Quarter 2022 Financial Results and Business Highlights

14 Nov 2022 15:01:01 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference

09 Nov 2022 15:01:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Report Third Quarter 2022 Financial Results on Nov. 14, 2022

07 Nov 2022 15:01:00 By Nasdaq GlobeNewswire

Acumen Publishes Phase 1 Trial Design and Clinical Development Plan for ACU193, an Anti-Amyloid Beta Oligomer Antibody for Alzheimer’s Disease

01 Nov 2022 07:00:02 By Nasdaq GlobeNewswire

Acumen’s ACU193, an Anti-Amyloid Beta Oligomer Antibody, Granted FDA Fast Track Designation for Alzheimer's Disease

24 Oct 2022 07:00:01 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals Reports Financial Results for Second Quarter 2022 and Business Highlights

15 Aug 2022 15:05:02 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 15, 2022

08 Aug 2022 15:15:00 By Nasdaq GlobeNewswire

Acumen presents poster describing method to standardize amyloid beta oligomer assays supporting therapeutic development for early Alzheimer’s disease

01 Aug 2022 09:30:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Participate in Upcoming Investor and Scientific Conferences

26 Jul 2022 15:15:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals Reports Financial Results for First Quarter 2022 and Business Highlights

16 May 2022 15:05:01 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Report First Quarter 2022 Financial Results on May 16, 2022

11 May 2022 16:08:41 By Nasdaq GlobeNewswire

Comprehensive Analysis in Frontiers in Neuroscience Highlights Acumen Pharmaceuticals’ New Approach to Treating Alzheimer's Disease

27 Apr 2022 07:00:01 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals Reports Financial Results for Full Year Ended December 31, 2021 and Business Highlights

28 Mar 2022 15:05:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results on March 28, 2022

16 Mar 2022 15:15:00 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Present at Upcoming Investor Conferences

08 Nov 2021 07:00:01 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals to Present Clinical Trial Design for INTERCEPT-AD, the Phase 1 Placebo-Controlled, Single- and Multiple-Dose Clinical Trial of ACU193, at 2021 Clinical Trials on Alzheimer’s Disease (CTAD) Conference

02 Nov 2021 07:00:01 By Nasdaq GlobeNewswire

Acumen Announces First Patient Dosed in a Phase 1 Clinical Trial of ACU193, a Monoclonal Antibody that Selectively Targets Toxic Aβ Oligomers for the Treatment of Early Alzheimer’s Disease

07 Oct 2021 07:00:01 By Nasdaq GlobeNewswire

Acumen Pharmaceuticals Reports Financial Results for Second Quarter 2021 and Business Highlights

16 Aug 2021 15:05:01 By Nasdaq GlobeNewswire